Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSL-1502 in HER2-negative BRCA-mutated Breast Cancer
NCT05420779Phase 2Recruiting
- Sponsor
- Tasly Group
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSL-1502 in breast cancer, sponsored by Tasly Group. Started Jun 2022; status: recruiting.
02
Drugs
TSL-1502
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05420779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420779.